STATUS OF A T POLYMORPHISM IN EXON II OF KINASE INSERT DOMAIN GENE IN WOMEN WITH PREMATURE OVARIAN FAILURE
Journal Title: International Journal of Drug Regulatory Affairs - Year 2015, Vol 3, Issue 1
Abstract
Ovarian failure is defined as cessation of ovarian function under the age of 40 and it is characterized by amenorrhea hypo estrogenism and elevated gonadotrophin serum levels leading to infertility. Ovarian failure affects 1% of women. Causes of ovarian failure are extremely heterogenous. Ovarian failure is caused either by accelerated loss of eggs or the follicles themselves become less responsive to hormonal stimulation. It is high levels of gonadotrophins (luteinizing hormone and follicle stimulating hormone) hormonal defects may cause severe cardio vascular consequences and leads to the early onset of osteoporosis. Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. VEGF is involved in the process of angiogenesis for the development of Graffian follicle an important feature of growing follicle which has been arrested in the primordial follicular stage .VEGF mediates the process of angiogenesis through its receptors I and II.. Receptor II is known as Kinase insert domain receptor, is a type III receptor tyrosine Kinase.KDR is located at 4q11-q12.The main objective of this study was to screen the mutations in Kinase insert domain by using the techniques DNA isolation, Polymerase chain reaction and restriction fragment length polymorphism.
Authors and Affiliations
RGB Ali H. Hasan, Sujatha M
Keywords
Related Articles
- EP ID EP338285
- DOI -
- Views 72
- Downloads 0
FORMULATION DEVELOPMENT AND IN VITRO EVALUATION OF FLOATING TABLETS OF LAFUTIDINE BY EMPLOYING EFFERVESCENT TECHNOLOGY
In the present research work gastro retentive floating matrix formulation of Lafutidine by using various polymers were developed. Initially analytical method development was done for the drug molecule. Absorption maxima...
A REVIEW ON DRUG APPROVAL PROCESS FOR US, EUROPE AND INDIA
Developing a new drug requires great amount of research work in chemistry, manufacturing, controls, preclinical science and clinical trials. Drug reviewers in regulatory agencies around the world bear the responsibility...
GERMANY PATENT SYSTEM – AN OVERVIEW
Patent is one of the intellectual property rights, by which the innovator gets exclusive rights or legal monopoly grated to an individual or a firm to make use or sell or reproduce and excluding others from doing so. The...
RISK ANALYSIS EVALUATION OF PIROXICAM 20MG CAPSULES MANUFACTURE PROCESS BY FMEA TECHNIQUE
This paper presents an application of FMEA (Failure Mode and Effects Analysis) on the manufacturing process of Piroxicam 20mg capsules, with the objective of identifying possible failures and creates subsidies for improv...
Understanding the globally harmonized system of classification and Labeling of Chemicals-The Purple Book
Global Harmonized System (GHS), relating to hazard chemicals, is a process of making a regulation among countries uniform to the extent possible so as to benefit an industry to export its products to several countries wi...